Toulouse, May 29th, 2017 (06:00 PM CEST) – VEXIM (FR0011072602 – ALVXM), a medical device company specializing in the minimally invasive treatment of vertebral fractures, today announces it has received the regulatory approval from ANVISA (1), Brazil’s National Health Surveillance Agency, in order to commercialize the SpineJack® in Brazil.
The approval from ANVISA is a key achievement opening a new opportunity for VEXIM in this important international market with untapped potential. This clearance will provide us with new growth opportunities in this key Latin American market. VEXIM estimates that Brazil alone today represents a €15 million market in the vertebral compression fractures field.

 

“This approval will enable us to have substantial growth in our international business. The Company is expecting to initiate export to Brazil in the coming months, after the conclusion of the product’s evaluation process and of distribution partnerships”, said Vincent Gardès, CEO of VEXIM.